NPR SHOTS – The FDA has confirmed the nation is experiencing a shortage of Adderall after many pharmacies around the country have been unable to fill prescriptions and keep up with demand.
The drug is used to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
Expected recovery times for manufacturers’ supplies of the prescription vary. Teva Pharmaceuticals, which sells the most Adderall in the U.S., has a 10 mg dosage of Adderall that is expected to rebound in October. But many of its generic brand offerings aren’t expected to recover until March 2023.
Manufacturer SpecGX’s higher doses won’t recoup until January 2023, while Rhodes Pharmaceuticals has a shortage of an active ingredient.
“An increase in ADHD diagnoses has been driving up demand for Adderall.”
Bloomberg health reporter Ike Swetlitz told NPR last month the shortages began due to a labor shortage at Teva, causing production delays that began showing up at other companies … READ MORE.